What's Going On With VistaGen Therapeutics Stock?
Portfolio Pulse from Adam Eckert
VistaGen Therapeutics Inc's stock is trading lower after a 675% surge on Monday following the announcement of positive results from its Phase 3 PALISADE-2 trial of fasedienol nasal spray for adults with social anxiety disorder. The trial met primary and secondary endpoints, marking the first positive U.S. Phase 3 study of a therapy for social anxiety disorder in over 15 years. Maxim Group analyst Jason McCarthy upgraded VistaGen from Hold to Buy and set a $30 price target.
August 08, 2023 | 1:35 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
VistaGen Therapeutics' stock is expected to experience volatility following the announcement of positive results from its Phase 3 trial and an upgrade from Maxim Group analyst.
The stock surged by 675% following the announcement of positive results from its Phase 3 trial, indicating a strong market reaction. However, the stock is now trading lower, suggesting a pullback after the initial surge. The upgrade from Maxim Group analyst could provide some support to the stock price, but overall, the stock is likely to experience volatility in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100